Chengdu Shengnuo Biotechnology Innovation Board passed

Chengdu Shengnuo Biotechnology Innovation Board passed

According to the 117th and 118th review meetings of the stock listing committee of the science and Technology Innovation Board held on December 11, 2020, the results of the review released show that all four enterprises have passed the meeting! On the same day, all four enterprises listed in the 55th review meeting of the GEM Listing Committee in 2020 passed the meeting.

Chengdu shengnuo biotechnology passed

Chengdu Shengnuo Biotechnology Co., Ltd. is a high-tech enterprise with the core technology of peptide synthesis and modification. It has advanced and efficient peptide drug process research and development and large-scale production capacity.

Its main business includes providing pharmaceutical research and customized production services for domestic and foreign pharmaceutical enterprises in the research and development of polypeptide innovative drugs.

Its independent research and development, production and sales are of great significance at home and abroad We have large market capacity and strong competitiveness of polypeptide generic drugs and pharmaceutical products, as well as polypeptide drug production technology transfer services.

In addition, Shengnuo Biotechnology is also engaged in the processing of levosimendan preparations and the production and export of levosimendan API.

Shengnuo Biotechnology has selected polypeptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development.

It has mastered the large-scale production technology of 15 varieties of API. Among them, 7 varieties have obtained production approval in China, 8 varieties have obtained DMF record (activation status) in the United States,

and 7 polypeptide preparation varieties developed by extension have obtained 11 production approval documents in China, The products cover the fields of immune system diseases, tumors, cardiovascular, chronic hepatitis B, diabetes, AIDS and obstetric diseases.

In September 2014, Guojin securities and Shengnuo Biotechnologysigned the coaching agreement.

In April 2018, after friendly negotiation, both parties agreed to terminate the cooperation and terminate the counseling agreement signed by both parties. On September 26, 2018, Shengnuo Biotechnologyreceived the guidance of Minsheng securities.

On May 8, 2019, Shengnuo Biotechnologyapplied to be listed on the sci tech Innovation Board of Shanghai Stock Exchange; in June 2019,Shengnuo Biotechnologysaid that according to the development needs of the company, the original application was changed from the original application to be listed on the sci tech Innovation Board of Shanghai Stock Exchange to the venture capital market of Shenzhen Stock Exchange.

On May 27, 2020,Shengnuo Biotechnologywill change its listing board from Shenzhen Stock Exchange growth enterprise market to Shanghai Stock Exchange science and technology innovation board.

The IPO of Shengnuo Biotechnologyplans to raise 433.28 million yuan, 206.53 million yuan is planned to be used for the 395 kg / a peptide API production line project, 168.42 million yuan is to be used for the preparation industrialization technology transformation project, and 58.33 million yuan is to be used for the upgrading project of Engineering Technology Center.